Literature DB >> 15496154

C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis.

Gopala K Rangan1, Jeffrey W Pippin, William G Couser.   

Abstract

BACKGROUND: In human focal segmental glomerulosclerosis (FSGS), the tubulointerstitial deposition of the complement (C5b-9) membrane attack complex is correlated with interstitial myofibroblast accumulation and proteinuria. Here, we hypothesized that C5b-9 formation regulates renal myofibroblast accumulation in Adriamycin nephropathy.
METHODS: Adriamycin nephropathy was induced in complement C6-sufficient (C6+) and C6-deficient (C6-) piebold viral glaxo (PVG) rats. Groups of animals (N= 7 to 8 each) were examined on days 21 and 42. A group of C6+ animals, injected with vehicle, served as the control group.
RESULTS: C6+ and C6- rats with Adriamycin nephropathy had equivalent proteinuria. C5b-9 deposition was increased and present on the apical surface of proximal tubular epithelial cells (day 21 and 42) and peritubular region (day 42 only) in C6+ rats with Adriamycin nephropathy, and absent in C6- rats. Peritubular myofibroblast accumulation increased in a time-dependent manner in C6+ proteinuric rats (control 1.2 +/- 0.4; Adriamycin nephropathy day 21 11.0 +/- 0.7; Adriamycin nephropathy day 42 19.8 +/- 1.7 cells per high power field). In C6- rats this increase was blunted by 87% and 56% on days 21 and 42, respectively (P < 0.01), and was associated with reduced interstitial extracellular matrix (ECM) deposition. Tubulointerstitial injury, tubular vimentin and interstitial monocyte accumulation were also reduced in C6- rats with Adriamycin nephropathy on day 21, but not at day 42. In contrast, the increase in periglomerular myofibroblast accumulation and glomerulosclerosis in Adriamycin nephropathy were not altered by C6 deficiency.
CONCLUSION: These data suggest that glomerular ultrafiltration of complement components and the intratubular formation of C5b-9 is a specific promotor of peritubular myofibroblast accumulation in FSGS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496154     DOI: 10.1111/j.1523-1755.2004.00957.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

Review 1.  The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio Alvim Brito-Melo; Fábio Tadeu Lourenço Guimarães; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões e Silva
Journal:  Inflamm Res       Date:  2014-01       Impact factor: 4.575

2.  The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells.

Authors:  Brandon Renner; Kathrin Coleman; Ryan Goldberg; Claudia Amura; Amanda Holland-Neidermyer; Kathryn Pierce; Heather N Orth; Hector Molina; Viviana P Ferreira; Claudio Cortes; Michael K Pangburn; V Michael Holers; Joshua M Thurman
Journal:  J Immunol       Date:  2010-07-30       Impact factor: 5.422

3.  Membranoproliferative pattern of glomerular injury associated with complement component 9 deficiency due to Arg95Stop mutation.

Authors:  Takayoshi Miura; Shin Goto; Seitaro Iguchi; Hisaki Shimada; Mitsuhiro Ueno; Shin-ichi Nishi; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2010-11-06       Impact factor: 2.801

4.  C5b-9 does not mediate tubulointerstitial injury in experimental acute glomerular disease characterized by selective proteinuria.

Authors:  Gopala K Rangan
Journal:  World J Nephrol       Date:  2016-05-06

Review 5.  Renal fibrosis: novel insights into mechanisms and therapeutic targets.

Authors:  Peter Boor; Tammo Ostendorf; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2010-09-14       Impact factor: 28.314

Review 6.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

Review 7.  Monoclonal antibodies for podocytopathies: rationale and clinical responses.

Authors:  Maddalena Marasà; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2009-06       Impact factor: 28.314

8.  Role of complement 3 in TNF-α-induced mesenchymal transition of renal tubular epithelial cells in vitro.

Authors:  Jianxin Wan; Xueli Zhou; Jiong Cui; Zhenhuan Zou; Yanfang Xu; Danyu You
Journal:  Mol Biotechnol       Date:  2013-05       Impact factor: 2.695

9.  C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy.

Authors:  Ziyong Tang; Bao Lu; Ellen Hatch; Steven H Sacks; Neil S Sheerin
Journal:  J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 10.121

Review 10.  Druggability of lipid metabolism modulation against renal fibrosis.

Authors:  Yuan-Yuan Chen; Xiao-Guang Chen; Sen Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.